

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 62386-015		SERIAL NO. 09/893,346	
				APPLICANT Wayne D. COMPER			
				FILING DATE June 28, 2001		GROUP 1648	

O I P E
 JAN 22 2002
 PATENT & TRADEMARK OFFICE 8905

RECEIVED
 JAN 24 2002
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
SAB ↓	5,246,835	9/21/1993	Suzuki et al.	435	7.95		
	5,534,431	7/9/96	McDonald	435	240.27		
	5,654,158	8/5/97	McDonald	435	7.1		
	5,908,925	6/1/1999	Cohen et al.	536	23.53		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
SAB ↓	514,928 A2	11/25/92	EP	—	—		
	4,336,498 A1	4/27/95	Germany (abstract only)	—	—		
	6082446	3/22/94	Japan	—	—		
	WO 00/37944	3/29/2000	WIPO (PCT/IB99/02029)	—	—		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
SAB ↓	<i>Proceedings of the Society for Experimental Biology and Medicine</i> , December 1997. 216(3):41423. Sabatino, B. and Van Liew, J.B., The renal handling of IgG in the aging rate and in experimental kidney disease.						
	<i>Kidney International</i> , February 1991. 39(2):307-11. Ohta, K. et al., Urinary excretion of endothelin-1 in normal subjects and patients with renal disease.						
	<i>Journal of Chromatography</i> , 29 July 1988. 429:3150-44. Weber, M.H., Urinary protein analysis.						
	<i>Clinical Nephrology</i> , March 1979, 11(3): 140-41. Blainey, J.D. and Terry, J.M., Urinary fibrinogen degradation products and differential protein clearances in renal disease.						
	<i>British Medical Journal</i> , 22 February 1975. 1(5955): 419-22. Hall, C.L. et al., Urinary fibrin-fibrinogen degradation products in nephrotic syndrome.						
	"Protein Degradation During Renal Passage in Normal Kidneys is Inhibited in Experimental Albuminuria", by Osicka et al., <i>Clinical Science</i> (1997) Vol. 93, pp. 65-72.						
SAB ↓	"Fractional Clearance of Albumin is Influenced by its Degradation During Renal Passage", by Osicka et al., <i>Clinical Science</i> (1997) Vol. 93, pp. 557-564.						
EXAMINER <i>Haley A. Boen</i>				DATE CONSIDERED <i>September 4, 2002</i>			

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

ATTY. DOCKET NO.
62386-015

SERIAL NO.
09/893,346

APPLICANT
Wayne D. COMPER

FILING DATE
June 28, 2001

GROUP
1648

(PTO-1449)

RECEIVED
JAN 24 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SUB	"Alterations in Renal Degradation of Albumin in Early Experimental Diabetes in the Rat: A New Factor in the Mechanism of Albuminuria" by Burne et al., Clinical Science (1998), Vol. 95, pp. 67-72.
	"Glomerular Capillary Wall Permeability to Albumin and Horseradish Peroxidase", by Osicka et al., Nephrology 1996, Vol. 2, pp. 199-212.
	'The Return of Glomerular-Filtered Albumin to the Rat Renal Vein', by Eppel, et al., Kidney International, Vol. 55, (1999), pp. 1861-1870.
	"Glomerular Charge Selectivity for Anionic and Neutral Horseradish Peroxidase", by Osicka, et al., Kidney International, Vol. 47 (1995), pp. 1630-1637.
	"Fractional Clearance of High Molecular Weight Proteins in Conscious Rats Using a Continuous Infusion Method", by Burne et al., Kidney International, Vol. 55, (1999), pp. 261-270.
	"Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats", T. M. Osicka et al., Diabetologia, (2001), pp. 230-236.
	"Evaluation of a New Fluorescent Dye Method to Measure Urinary Albumin in Lieu of Urinary Total Protein", Alfredo A. Pegoraro, MD et al., American Journal of Kidney Diseases, Vol. 35, No. 4 (April), 2000, pp. 739-744.
	Pharmacia Biotech BioDirectory catalog, p. 405. (1996)
	BioRad Life Science Research Products catalog, p. 97. (1993)

EXAMINER

Hay J. D.

DATE CONSIDERED

September 4, 2002